

Non-endoscopic diagnosis of atrophic gastritis with a biopsied gastric histology and serum levels of gastrin-17 and pepsinogen I

European Journal of Gastroenterology and Hepatology
15, 885-891

DOI: 10.1097/00042737-200308000-00009

Citation Report

#	ARTICLE	IF	CITATIONS
1	In through the out door. European Journal of Gastroenterology and Hepatology, 2003, 15, 877-879.	0.8	38
2	Serum Levels of Pepsinogen I, Pepsinogen II, and Gastrin-17 in the Course of Helicobacter pylori Gastritis in Pediatrics. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 568-569.	0.9	15
3	Diagnosis of Helicobacter pylori Infection. Helicobacter, 2004, 9, 7-14.	1.6	40
5	Protocolo diagn?stico de las anemias macroc?ticas. Medicine, 2004, 9, 1291-1292.	0.0	0
6	Serum Levels of Pepsinogen I, Pepsinogen II, and Gastrin-17 in the Course of Helicobacter pylori Gastritis in Pediatrics. Journal of Pediatric Gastroenterology and Nutrition, 2004, 39, 569-570.	0.9	1
7	Gastric Acidity in Patients with Follicular Gastritis is Significantly Reduced, but Can be Normalized After Eradication for Helicobacter pylori. Helicobacter, 2005, 10, 256-265.	1.6	26
8	Recovery of gastric function after Helicobacter pylori eradication in subjects with body atrophic gastritis: Prospective 4-year study. Journal of Gastroenterology and Hepatology (Australia), 2005, 20, 1661-1666.	1.4	6
9	Diagnostic accuracy of the serum profile of gastric mucosa in relation to histological and morphometric diagnosis of atrophy. Alimentary Pharmacology and Therapeutics, 2005, 22, 1139-1146.	1.9	54
10	Histologic and serum risk markers for noncardia early gastric cancer. International Journal of Cancer, 2005, 115, 463-469.	2.3	66
11	Gastrin (G) cells and somatostatin (D) cells in patients with dyspeptic symptoms: Helicobacter pylori associated and non-associated gastritis. Journal of Clinical Pathology, 2005, 58, 927-931.	1.0	53
12	Real-Time Detection of Helicobacter Pylori Infection and Atrophic Gastritis: Comparison between Conventional Methods and a Novel Device for Gastric Juice Analysis During Endoscopy. Endoscopy, 2005, 37, 966-976.	1.0	16
13	Biomarkers in Patients with Gastric Inflammation: A Systematic Review. Digestion, 2005, 72, 164-180.	1.2	47
14	Normal serum pepsinogen I levels in adults: A population-based study with special reference to Helicobacter pylori infection and parietal cell antibodies. Scandinavian Journal of Clinical and Laboratory Investigation, 2005, 65, 291-300.	0.6	11
15	Clinical usefulness of serum pepsinogens I and II, gastrin-17 and anti-Helicobacter pylori antibodies in the management of dyspeptic patients in primary care. Digestive and Liver Disease, 2005, 37, 501-508.	0.4	63
16	Noninvasive Versus Histologic Detection of Gastric Atrophy in a Hispanic Population in North America. Clinical Gastroenterology and Hepatology, 2006, 4, 306-314.	2.4	72
18	Early diagnosis of early gastric cancer. European Journal of Gastroenterology and Hepatology, 2006, 18, 821-829.	0.8	95
19	The gastric mucosa in gastric cancer patients in a low-incidence area. European Journal of Gastroenterology and Hepatology, 2006, 18, 1085-1093.	0.8	5
20	The 13 carbon urea breath test for the diagnosis of Helicobacter pylori infection in subjects with atrophic gastritis: evaluation in a primary care setting. Alimentary Pharmacology and Therapeutics, 2006, 24, 643-650.	1.9	14

#	ARTICLE	IF	CITATIONS
21	Detection and treatment of early cancer in high-risk populations. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2006, 20, 745-765.	1.0	27
22	Ultrasensitive detection of pepsinogen I and pepsinogen II by a time-resolved fluoroimmunoassay and its preliminary clinical applications. <i>Analytica Chimica Acta</i> , 2006, 571, 74-78.	2.6	33
23	Usefulness of Serum Pepsinogens in Helicobacter pylori Chronic Gastritis: Relationship With Inflammation, Activity, and Density of the Bacterium. <i>Digestive Diseases and Sciences</i> , 2006, 51, 1791-1795.	1.1	50
24	Symptoms and diagnosis of gastric cancer at early curable stage. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2006, 20, 697-708.	1.0	74
25	Reply to Dr. Tucci. <i>Endoscopy</i> , 2006, 38, 286.	1.0	1
26	Real-Time Testing for Helicobacter Pylori and Atrophy of the Gastric Body: Reply to the Editorial of D. Graham. <i>Endoscopy</i> , 2006, 38, 285-286.	1.0	2
27	Relationship among serum pepsinogens, serum gastrin, gastric mucosal histology and H. pylori virulence factors in a paediatric population. <i>Scandinavian Journal of Gastroenterology</i> , 2006, 41, 524-531.	0.6	21
28	Prevalence of Chronic Atrophic Gastritis in Different Parts of the World. <i>Cancer Epidemiology Biomarkers and Prevention</i> , 2006, 15, 1083-1094.	1.1	122
29	Two distinct aetiologies of cardia cancer; evidence from premorbid serological markers of gastric atrophy and Helicobacter pylori status. <i>Gut</i> , 2007, 56, 918-925.	6.1	149
30	Epidemiological trends of pre-malignant gastric lesions: a long-term nationwide study in the Netherlands. <i>Gut</i> , 2007, 56, 1665-1670.	6.1	67
31	Assessing the severity of atrophic gastritis. <i>European Journal of Gastroenterology and Hepatology</i> , 2007, 19, 1059-1063.	0.8	8
32	Non-invasive assessment of chronic liver and gastric diseases. <i>Clinica Chimica Acta</i> , 2007, 381, 39-49.	0.5	18
33	Is GastroPanel serum assay useful in the diagnosis of Helicobacter pylori infection and associated gastritis in children?. <i>Diagnostic Microbiology and Infectious Disease</i> , 2007, 57, 35-38.	0.8	18
34	Helicobacter pylori Detection and Antimicrobial Susceptibility Testing. <i>Clinical Microbiology Reviews</i> , 2007, 20, 280-322.	5.7	595
36	Clinical usefulness of gastric-juice analysis in 2007: the stone that the builders rejected has become the cornerstone. <i>Gastrointestinal Endoscopy</i> , 2007, 66, 881-890.	0.5	28
37	Gastric Preneoplastic Lesions and Epithelial Dysplasia. <i>Gastroenterology Clinics of North America</i> , 2007, 36, 813-829.	1.0	71
38	Importance of atrophic gastritis in diagnostics and prevention of gastric cancer: Application of plasma biomarkers. <i>Scandinavian Journal of Gastroenterology</i> , 2007, 42, 2-10.	0.6	85
39	Detección de lesiones preneoplásicas gástricas mediante niveles séricos de pepsinógeno en población chilena. <i>Revista Medica De Chile</i> , 2007, 135, .	0.1	4

#	ARTICLE	IF	CITATIONS
40	Screening of atrophic gastritis and gastric cancer by serum pepsinogen, gastrin-17 and Helicobacter pylori immunoglobulin G antibodies. <i>Journal of Digestive Diseases</i> , 2007, 8, 15-22.	0.7	75
41	Consensus on chronic gastritis in China ? Second National Consensus Meeting on Chronic Gastritis (14-16 September 2006 Shanghai, China). <i>Journal of Digestive Diseases</i> , 2007, 8, 107-119.	0.7	38
42	The Detection, Surveillance and Treatment of Premalignant Gastric Lesions Related to Helicobacter pylori Infection. <i>Helicobacter</i> , 2007, 12, 1-15.	1.6	113
43	Persisting Chronic Gastritis and Elevated <i>Helicobacter pylori</i> Antibodies after Successful Eradication Therapy. <i>Helicobacter</i> , 2007, 12, 605-608.	1.6	19
44	Epidemiology of Premalignant Gastric Lesions: Implications for the Development of Screening and Surveillance Strategies. <i>Helicobacter</i> , 2007, 12, 22-31.	1.6	77
45	Gastric Status and Vitamin B12 Levels in Cardiovascular Patients. <i>Digestive Diseases and Sciences</i> , 2007, 52, 2186-2189.	1.1	5
46	Helicobacter pylori et néoplasies gastriques. <i>Journal Africain D'Hepato-Gastroenterologie</i> , 2007, 1, 1-4.	0.0	1
47	Evaluation of Gastric Cancer Risk Using Topography of Histological Gastritis: A Large-scaled Cross-sectional Study. <i>Digestive Diseases and Sciences</i> , 2008, 53, 1818-1823.	1.1	27
48	Atrophic gastritis: deficient complex I of the respiratory chain in the mitochondria of corpus mucosal cells. <i>Journal of Gastroenterology</i> , 2008, 43, 780-788.	2.3	34
49	Association of <i>Helicobacter pylori</i> infection with chronic atrophic gastritis: Meta-analysis according to type of disease definition. <i>International Journal of Cancer</i> , 2008, 123, 874-881.	2.3	54
50	Risk of gastric cancer in asymptomatic, middle-aged Japanese subjects based on serum pepsinogen and <i>Helicobacter pylori</i> antibody levels. <i>International Journal of Cancer</i> , 2008, 123, 917-926.	2.3	66
51	Neoplastic precursor lesions of the upper gastrointestinal tract. <i>Diagnostic Histopathology</i> , 2008, 14, 437-452.	0.2	12
52	The Role of Serum Pepsinogen and Gastrin Test for the Detection of Gastric Cancer in Korea. <i>Helicobacter</i> , 2008, 13, 146-156.	1.6	95
53	Helicobacter pylori eradication improves gastric histology and decreases serum gastrin, pepsinogen I and pepsinogen II levels in patients with duodenal ulcer. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2008, 23, 1666-1671.	1.4	41
54	Upper abdominal symptoms in patients with Type 1 diabetes: unrelated to impairment in gastric emptying caused by autonomic neuropathy. <i>Diabetic Medicine</i> , 2008, 25, 570-577.	1.2	62
55	Serum gastrin and pepsinogens do not correlate with the different grades of severity of gastroesophageal reflux disease: a matched case-control study. <i>Alimentary Pharmacology and Therapeutics</i> , 2008, 28, 491-496.	1.9	22
56	Non-invasive tests in gastric diseases. <i>Digestive and Liver Disease</i> , 2008, 40, 523-530.	0.4	85
57	Occurrence and Risk Factors for Autoimmune Thyroid Disease in Patients with Atrophic Body Gastritis. <i>American Journal of Medicine</i> , 2008, 121, 136-141.	0.6	91

#	ARTICLE	IF	CITATIONS
58	Screening for gastric cancer in Asia: current evidence and practice. <i>Lancet Oncology</i> , The, 2008, 9, 279-287.	5.1	744
59	Serum Pepsinogen I, Pepsinogen II, and Gastrin 17 in Relatives of Gastric Cancer Patients: Comparative Study With Type and Severity of Gastritis. <i>Clinical Gastroenterology and Hepatology</i> , 2008, 6, 174-179.	2.4	56
60	T1078 The Validity of a Biomarker Method for Indirect Detection of Gastric Mucosal Atrophy Versus Standard Histopathology. <i>Gastroenterology</i> , 2008, 134, A-478.	0.6	0
61	Serum biomarkers provide an accurate method for diagnosis of atrophic gastritis in a general population: The Kalixanda study. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1448-1455.	0.6	102
62	Serum biomarkers for atrophic gastritis and antibodies against <i>Helicobacter pylori</i> in the elderly: Implications for vitamin B ₁₂ , folic acid and iron status and response to oral vitamin therapy. <i>Scandinavian Journal of Gastroenterology</i> , 2008, 43, 1050-1056.	0.6	33
63	Combination of gastric atrophy, reflux symptoms and histological subtype indicates two distinct aetiologies of gastric cardia cancer. <i>Gut</i> , 2008, 57, 298-305.	6.1	161
64	Gastritis and gastric atrophy. <i>Current Opinion in Gastroenterology</i> , 2008, 24, 682-686.	1.0	26
65	How to Interpret Biopsies for "Gastritis", 2008, 13, 157-166.		1
66	Comparison Between Serology and Histology in the Diagnosis of Advanced Gastric Body Atrophy. <i>Journal of Clinical Gastroenterology</i> , 2008, 42, 18-22.	1.1	26
67	Optimal Approach to Obtaining Mucosal Biopsies for Assessment of Inflammatory Disorders of the Gastrointestinal Tract. <i>American Journal of Gastroenterology</i> , 2009, 104, 774-783.	0.2	0
68	Pernicious anemia: New insights from a gastroenterological point of view. <i>World Journal of Gastroenterology</i> , 2009, 15, 5121.	1.4	193
69	Optimal Approach to Obtaining Mucosal Biopsies for Assessment of Inflammatory Disorders of the Gastrointestinal Tract. <i>American Journal of Gastroenterology</i> , 2009, 104, 774-783.	0.2	85
70	Reassessment of Intrinsic Factor and Parietal Cell Autoantibodies in Atrophic Gastritis With Respect to Cobalamin Deficiency. <i>American Journal of Gastroenterology</i> , 2009, 104, 2071-2079.	0.2	130
71	The Validity of a Biomarker Method for Indirect Detection of Gastric Mucosal Atrophy Versus Standard Histopathology. <i>Digestive Diseases and Sciences</i> , 2009, 54, 2377-2384.	1.1	60
72	Influence of gastric mucosal status on success of stepwise acid suppressive therapy for dyspepsia. <i>Alimentary Pharmacology and Therapeutics</i> , 2009, 30, 82-89.	1.9	0
73	Serum Levels of Leptin As Marker For Patients At High Risk of Gastric Cancer. <i>Helicobacter</i> , 2009, 14, 596-604.	1.6	15
74	GastroPanel: Evaluation of the usefulness in the diagnosis of gastro-duodenal mucosal alterations in children. <i>Clinica Chimica Acta</i> , 2009, 402, 54-60.	0.5	37
75	The use of clinical, histologic, and serologic parameters to predict the intragastric extent of intestinal metaplasia: a recommendation for routine practice. <i>Gastrointestinal Endoscopy</i> , 2009, 70, 18-25.	0.5	42

#	ARTICLE	IF	CITATIONS
76	Clinical use of proton-pump inhibitors but not H ₂ -blockers or antacid/alginate raises the serum levels of amidated gastrin-17, pepsinogen I and pepsinogen II in a random adult population. <i>Scandinavian Journal of Gastroenterology</i> , 2009, 44, 564-570.	0.6	41
77	Clinical meaning of pepsinogen test and <i>Helicobacter pylori</i> serology in the health check-up population in Korea. <i>European Journal of Gastroenterology and Hepatology</i> , 2009, 21, 606-612.	0.8	44
78	Clinical Aspects of Gastric Cancer and <i>Helicobacter pylori</i> Screening, Prevention, and Treatment. <i>Helicobacter</i> , 2010, 15, 40-45.	1.6	16
79	Metabolomic investigation of gastric cancer tissue using gas chromatography/mass spectrometry. <i>Analytical and Bioanalytical Chemistry</i> , 2010, 396, 1385-1395.	1.9	122
80	Gastritis Induced by <i>Helicobacter pylori</i> Infection in Experimental Rats. <i>Digestive Diseases and Sciences</i> , 2010, 55, 2770-2777.	1.1	11
81	Assessment of Degree of Health of the Stomach by Concomitant Measurement of Serum Pepsinogen and Serum <i>Helicobacter Pylori</i> Antibodies. <i>International Journal of Biological Markers</i> , 2010, 25, 207-212.	0.7	32
83	<i>Helicobacter pylori</i> infection and current clinical areas of contention. <i>Current Opinion in Gastroenterology</i> , 2010, 26, 618-623.	1.0	40
84	Prevalence of atrophic gastritis in dyspeptic patients in Piedmont. A survey using the GastroPanel test. <i>Clinical Chemistry and Laboratory Medicine</i> , 2010, 48, 1327-32.	1.4	16
85	<i>Helicobacter pylori</i> immunoproteomics in gastric cancer and gastritis of the carcinoma phenotype. <i>Expert Review of Proteomics</i> , 2010, 7, 239-248.	1.3	9
86	Gastrin: An Acid-Releasing, Proliferative and Immunomodulatory Peptide?. <i>Mini-Reviews in Medicinal Chemistry</i> , 2010, 10, 8-19.	1.1	11
87	Prevalence of undiagnosed advanced atrophic corpus gastritis in Finland: an observational study among 4,256 volunteers without specific complaints. <i>Scandinavian Journal of Gastroenterology</i> , 2010, 45, 1036-1041.	0.6	50
88	HLA-DRB1*03 and DRB1*04 are associated with atrophic gastritis in an Italian population. <i>Digestive and Liver Disease</i> , 2010, 42, 854-859.	0.4	20
89	Value of gastrin-17 in detecting antral atrophy. <i>Advances in Medical Sciences</i> , 2011, 56, 145-150.	0.9	33
90	The prevalence of premalignant gastric lesions in asymptomatic patients: Predicting the future incidence of gastric cancer. <i>European Journal of Cancer</i> , 2011, 47, 1211-1218.	1.3	59
91	Role of Natural Antioxidants in Gastritis. , 2011, , .		1
92	Gastric plasma biomarkers and Operative Link for Gastritis Assessment gastritis stage. <i>European Journal of Gastroenterology and Hepatology</i> , 2011, 23, 302-307.	0.8	21
93	Correlation of serum pepsinogens and gastrin-17 with atrophic gastritis in gastroesophageal reflux patients: A matched-pairs study. <i>Journal of Gastroenterology and Hepatology (Australia)</i> , 2011, 26, 82-89.	1.4	23
94	Usefulness of thyrogastic immune features as predictors of pernicious anaemia that lacks intrinsic factor antibody. <i>International Journal of Laboratory Hematology</i> , 2011, 33, 400-408.	0.7	3

#	ARTICLE	IF	CITATIONS
95	Diagnosis and Management of Pernicious Anemia. <i>Current Gastroenterology Reports</i> , 2011, 13, 518-524.	1.1	57
96	Accuracy and Cut-Off Values of Pepsinogens I, II and Gastrin 17 for Diagnosis of Gastric Fundic Atrophy: Influence of Gastritis. <i>PLoS ONE</i> , 2011, 6, e26957.	1.1	46
97	Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). <i>Endoscopy</i> , 2012, 44, 74-94.	1.0	594
98	Rationale in diagnosis and screening of atrophic gastritis with stomach-specific plasma biomarkers. <i>Scandinavian Journal of Gastroenterology</i> , 2012, 47, 136-147.	0.6	136
99	Autosomal Dominant MÃ©nÃ©trierÃ©like Disease. <i>Journal of Pediatric Gastroenterology and Nutrition</i> , 2012, 55, 717-720.	0.9	9
100	Impact of chronic <i>Helicobacter pylori</i> infection on Alzheimer's disease: preliminary results. <i>Neurobiology of Aging</i> , 2012, 33, 1009.e11-1009.e19.	1.5	108
101	Serum metabolic profiling of human gastric cancer based on gas chromatography/mass spectrometry. <i>Brazilian Journal of Medical and Biological Research</i> , 2012, 45, 78-85.	0.7	64
102	Low serum pepsinogen I and pepsinogen I/II ratio and <i>Helicobacter pylori</i> infection are associated with increased risk of gastric cancer: 14-year follow up result in a rural Chinese community. <i>International Journal of Cancer</i> , 2012, 130, 1614-1619.	2.3	42
103	Management of precancerous conditions and lesions in the stomach (MAPS): guideline from the European Society of Gastrointestinal Endoscopy (ESGE), European Helicobacter Study Group (EHSG), European Society of Pathology (ESP), and the Sociedade Portuguesa de Endoscopia Digestiva (SPED). <i>Virchows Archiv Fur Pathologische Anatomie Und Physiologie Und Fur Klinische Medizin</i> , 2012, 460, 19-46.	1.4	111
104	Eradication of gastric cancer is now both possible and practical. <i>Seminars in Cancer Biology</i> , 2013, 23, 492-501.	4.3	98
105	Stomach Duodenum Inflammatory Disease. , 2013, , 391-406.		0
106	Precancerous lesions in the stomach: From biology to clinical patient management. <i>Bailliere's Best Practice and Research in Clinical Gastroenterology</i> , 2013, 27, 205-223.	1.0	96
107	The association between precancerous gastric lesions and serum pepsinogens, serum gastrin, vascular endothelial growth factor, serum interleukin-1 Beta, serum toll-like receptor-4 levels and <i>Helicobacter pylori</i> Cag A status. <i>Clinics and Research in Hepatology and Gastroenterology</i> , 2013, 37, 302-311.	0.7	23
108	Biomarkers of <i>Helicobacter pylori</i> -associated gastric cancer. <i>Gut Microbes</i> , 2013, 4, 532-540.	4.3	20
109	Interobserver variation in assessment of gastric premalignant lesions. <i>European Journal of Gastroenterology and Hepatology</i> , 2013, 25, 694-699.	0.8	31
110	<i>Helicobacter pylori</i> infection and atrophic gastritis. <i>African Health Sciences</i> , 2013, 13, 112-7.	0.3	16
111	Gastric cancer: Prevention, screening and early diagnosis. <i>World Journal of Gastroenterology</i> , 2014, 20, 13842.	1.4	312
112	Pepsinogen II Can Be a Potential Surrogate Marker of Morphological Changes in Corpus before and after <i>H. pylori</i> Eradication. <i>BioMed Research International</i> , 2014, 2014, 1-7.	0.9	28

#	ARTICLE	IF	CITATIONS
113	Niveles sÃ©ricos de pepsinÃ³geno y su capacidad diagnÃ³stica de atrofia gÃ¡strica en diferentes poblaciones colombianas. Revista Colombiana De CancerologÃ­a, 2014, 18, 166-178.	0.0	0
114	Prevalence of gastric precancerous conditions. European Journal of Gastroenterology and Hepatology, 2014, 26, 378-387.	0.8	93
115	Accuracy of GastroPanel for the diagnosis of atrophic gastritis. European Journal of Gastroenterology and Hepatology, 2014, 26, 941-948.	0.8	54
116	Screening of Precancerous Gastric Lesions by Serum Pepsinogen, Gastrin-17, Anti-Helicobacter Pylori and Anti-Caga Antibodies in Dyspeptic Patients over 50 years Old in Guilan Province, North of Iran. Asian Pacific Journal of Cancer Prevention, 2014, 15, 7635-7638.	0.5	9
117	<i>Helicobacter pylori</i> associated chronic gastritis, clinical syndromes, precancerous lesions, and pathogenesis of gastric cancer development. World Journal of Gastroenterology, 2014, 20, 5461.	1.4	209
118	Metabolomic studies of human gastric cancer: Review. World Journal of Gastroenterology, 2014, 20, 8092.	1.4	55
119	Correlation between the Serum Pepsinogen I Level and the Symptom Degree in Proton Pump Inhibitor-Users Administered with a Probiotic. Pharmaceuticals, 2014, 7, 754-764.	1.7	12
120	Gastric mucin expression in first-degree relatives of gastric cancer patients. European Journal of Gastroenterology and Hepatology, 2014, 26, 710-714.	0.8	8
121	Secondary Prevention of Epidemic Gastric Cancer in the Model of <i>Helicobacter pylori</i> -Associated Gastritis. Digestive Diseases, 2014, 32, 265-274.	0.8	17
122	Screening of Gastric Cancer: Who, When, and How. Clinical Gastroenterology and Hepatology, 2014, 12, 135-138.	2.4	55
123	Fundic gland polyps accurately predict a low risk of future gastric carcinogenesis. Clinics and Research in Hepatology and Gastroenterology, 2014, 38, 505-512.	0.7	4
124	Biological Markers in Oral Squamous Cell Carcinoma. , 2014, , 273-312.		0
125	Temporal changes in serum biomarkers and risk for progression of gastric precancerous lesions: A longitudinal study. International Journal of Cancer, 2015, 136, 425-434.	2.3	35
126	Determination of Urinary 5-Hydroxyindoleacetic Acid as a Metabolomics in Gastric Cancer. Journal of Gastrointestinal Cancer, 2015, 46, 138-142.	0.6	14
127	A Laboratory Score in the Diagnosis of Autoimmune Atrophic Gastritis. Journal of Clinical Gastroenterology, 2015, 49, e1-e5.	1.1	33
128	The optimal serum pepsinogen cut-off value for predicting histologically confirmed atrophic gastritis. Digestive and Liver Disease, 2015, 47, 663-668.	0.4	23
129	Serum Pepsinogen Levels Are Correlated With Age, Sex and the Level of Helicobacter pylori Infection in Healthy Individuals. American Journal of the Medical Sciences, 2016, 352, 481-486.	0.4	17
130	The Diagnostic Value of Gastrin-17 Detection in Atrophic Gastritis. Medicine (United States), 2016, 95, e3599.	0.4	23

#	ARTICLE	IF	CITATIONS
131	Cutoff Pepsinogen Level for Predicting Unintended Eradicated Cases of <i>Helicobacter pylori</i> Infection in Subjects with Seemingly Normal Pepsinogen Levels. <i>Digestion</i> , 2017, 95, 229-236.	1.2	16
132	A Serological Biopsy Using Five Stomach-Specific Circulating Biomarkers for Gastric Cancer Risk Assessment: A Multi-Phase Study. <i>American Journal of Gastroenterology</i> , 2017, 112, 704-715.	0.2	81
133	Influence of laboratory-related and endoscopy-related factors on the assessment of serum pepsinogens and gastrin-17. <i>European Journal of Gastroenterology and Hepatology</i> , 2017, 29, 1340-1345.	0.8	7
134	<i>Helicobacter pylori</i> infection and serum level of pepsinogen are associated with the risk of metachronous gastric neoplasm after endoscopic resection. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 758-767.	1.9	18
135	Systematic review with meta-analysis: diagnostic performance of the combination of pepsinogen, gastrin-17 and anti- <i>Helicobacter pylori</i> antibodies serum assays for the diagnosis of atrophic gastritis. <i>Alimentary Pharmacology and Therapeutics</i> , 2017, 46, 657-667.	1.9	133
136	Serum pepsinogen and gastrin-17 as potential biomarkers for pre-malignant lesions in the gastric corpus. <i>Biomedical Reports</i> , 2017, 7, 460-468.	0.9	19
137	Premalignant gastric lesions in patients included in National colorectal cancer screening. <i>Radiology and Oncology</i> , 2017, 52, 7-13.	0.6	13
138	Serological Biomarker Panel (GastroPanel [®]): A Test for Non-Invasive Diagnosis of Dyspeptic Symptoms and for Comprehensive Detection of <i>Helicobacter pylori</i> Infection. <i>Biomarkers Journal</i> , 2017, 03, .	0.2	2
139	Atrophic and Metaplastic Progression in the Background Mucosa of Patients with Gastric Adenoma. <i>PLoS ONE</i> , 2017, 12, e0169456.	1.1	7
140	Chinese consensus on chronic gastritis (2017, Shanghai). <i>Journal of Digestive Diseases</i> , 2018, 19, 182-203.	0.7	52
141	Sero-prevalence of <i>Helicobacter pylori</i> CagA immunoglobulin G antibody, serum pepsinogens and haemoglobin levels in adults. <i>Scientific Reports</i> , 2018, 8, 17616.	1.6	7
142	Correlation between <i>Helicobacter pylori</i> Infection and Gastric Atrophy Examined in the Sera of Mongolian People. <i>Gastrointestinal Disorders</i> , 2019, 1, 241-252.	0.4	3
143	Combination of 15 lipid metabolites and motilin to diagnose spleen-deficiency FD. <i>Chinese Medicine</i> , 2019, 14, 16.	1.6	9
144	GastroPanel [®] Biomarker Assay: The Most Comprehensive Test for <i>Helicobacter pylori</i> Infection and Its Clinical Sequelae. A Critical Review. <i>Anticancer Research</i> , 2019, 39, 1091-1104.	0.5	24
145	Prevalence and determinants of serological evidence of atrophic gastritis among Arab and Jewish residents of Jerusalem: a cross-sectional study. <i>BMJ Open</i> , 2019, 9, e024689.	0.8	10
146	Current View on Autoimmune Gastritis. , 2019, , .		4
147	Serum Markers. , 2019, , 79-86.		0
149	Analysis of serum gastrin-17 and <i>Helicobacter pylori</i> antibody in healthy Chinese population. <i>Journal of Clinical Laboratory Analysis</i> , 2020, 34, e23518.	0.9	11

#	ARTICLE	IF	CITATIONS
150	Prevalence of atrophic gastritis in southwest China and predictive strength of serum gastrin-17: A cross-sectional study (SIGES). <i>Scientific Reports</i> , 2020, 10, 4523.	1.6	28
151	Serological Biomarker Test (GastroPanel [®]) in the Diagnosis of Functional Gastric Disorders, <i>Helicobacter pylori</i> and Atrophic Gastritis in Patients Examined for Dyspeptic Symptoms. <i>Anticancer Research</i> , 2021, 41, 811-819.	0.5	9
152	The Diagnostic Value of Serum Gastrin-17 and Pepsinogen for Gastric Cancer Screening in Eastern China. <i>Gastroenterology Research and Practice</i> , 2021, 2021, 1-8.	0.7	10
153	Gastric cancer detection using the serum pepsinogen test method. <i>Tumori</i> , 2021, , 030089162110149.	0.6	7
154	Association of <i>Helicobacter pylori</i> Infection and Host Cytokine Gene Polymorphism with Gastric Cancer. <i>Canadian Journal of Gastroenterology and Hepatology</i> , 2021, 2021, 1-12.	0.8	9
155	Value of GastroPanel in the diagnosis of atrophic gastritis. <i>Experimental and Therapeutic Medicine</i> , 2021, 22, 1347.	0.8	6
156	Polymorphisms in Pepsinogen C and miRNA Genes Associate with High Serum Pepsinogen II in Gastric Cancer Patients. <i>Microorganisms</i> , 2021, 9, 126.	1.6	4
157	Gastric Secretion. , 2010, , 817-832.e7.		3
158	Serum metabolomic profiling of human gastric cancer and its relationship with the prognosis. <i>Oncotarget</i> , 2017, 8, 110000-110015.	0.8	21
159	A Panel of Serum Biomarkers (GastroPanel [®]) in Non-invasive Diagnosis of Atrophic Gastritis. Systematic Review and Meta-analysis. <i>Anticancer Research</i> , 2016, 36, 5133-5144.	0.5	54
161	501 Evaluation of specific biochemical indicators of <i>Helicobacter pylori</i> -associated gastric cancer in Egypt. <i>Eastern Mediterranean Health Journal</i> , 2012, 18, 501-507.	0.3	5
162	Screening, Monitoring, and Treatment of Precancerous Atrophic Gastritis in the Prospective Study for Seven Years. <i>Asian Pacific Journal of Cancer Prevention</i> , 2020, 21, 331-336.	0.5	4
163	Serum biomarker tests are useful in delineating between patients with gastric atrophy and normal, healthy stomach. <i>World Journal of Gastroenterology</i> , 2009, 15, 853.	1.4	78
164	Possibility of non-invasive diagnosis of gastric mucosal precancerous changes. <i>World Journal of Gastroenterology</i> , 2004, 10, 3146.	1.4	19
165	Possible contribution of advanced statistical methods (artificial neural networks and linear) Tj ETQq0 0 0 rgBT /Overlock 10 Tf 50 187 T Journal of Gastroenterology, 2005, 11, 5867.	1.4	23
166	Low circulating levels of gastrin-17 in patients with Barrett's esophagus. <i>World Journal of Gastroenterology</i> , 2005, 11, 5988.	1.4	24
167	Non-invasive diagnosis of gastric mucosal atrophy in an asymptomatic population with high prevalence of gastric cancer. <i>World Journal of Gastroenterology</i> , 2006, 12, 7172.	1.4	25
168	Serum pepsinogen levels and their influencing factors: A population-based study in 6990 Chinese from North China. <i>World Journal of Gastroenterology</i> , 2007, 13, 6562.	1.4	32

#	ARTICLE	IF	CITATIONS
169	<i>Helicobacter pylori</i> infection in older people. World Journal of Gastroenterology, 2014, 20, 6364.	1.4	56
170	Screening for and surveillance of gastric cancer. World Journal of Gastroenterology, 2014, 20, 13681.	1.4	18
171	The Difference of Serum Gastrin-17 Level Based on Gastritis Severity and Helicobacter Pylori Infection. Open Access Macedonian Journal of Medical Sciences, 2019, 7, 1266-1269.	0.1	4
172	Clinical correlation between serum pepsinogen level and gastric atrophy in gastric neoplasm. Korean Journal of Internal Medicine, 2020, 35, 550-558.	0.7	18
173	Helicobacter pylori in humans: Where are we now?. Advanced Biomedical Research, 2014, 3, 63.	0.2	11
174	Assessing GastroPanel serum markers as a non-invasive method for the diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection. Open Journal of Gastroenterology, 2012, 02, 113-118.	0.1	5
175	Prevention Strategies for Gastric Cancer: A Global Perspective. Clinical Endoscopy, 2014, 47, 478.	0.6	107
176	The role of pepsinogen assays as surrogate markers of gastritis dynamics in population studies. , 2003, , 127-132.		0
177	The Serological Gastric Biopsy: A Non-endoscopic/Histopathologic Diagnostic Approach in Management of the Dyspeptic Patients. American Journal of Immunology, 2006, 2, 88-96.	0.1	2
178	Laboratory screening markers in gastroenterology - state of the art. Biomedical Papers of the Medical Faculty of the University Palacky, Olomouc, Czechoslovakia, 2013, 157, 91-97.	0.2	1
179	IDDTL: A Novel Identified Internet Data Transport Layer Mechanism. Journal of Networks, 2014, 9, .	0.4	0
180	Caveats in Diagnosis of Helicobacter Pylori Infection can be Avoided by a Panel of Serum Biomarkers (GastroPanel®). Journal of Carcinogenesis & Mutagenesis, 2016, 07, .	0.3	2
181	Non-Invasive Diagnosis of Gastroesophageal Reflux Disease Using Gastrin- and Pepsinogen-Based Tests. Proceedings of the Latvian Academy of Sciences, 2018, 72, 172-176.	0.0	0
182	Paciente con anemia perniciosa y cambios comportamentales. Repertorio De Medicina Y Cirugia, 2020, 29, .	0.0	0
183	Atrophic gastritis in Chernobyl nuclear power plant accident recovery workers in remote period. Medico-Biological and Socio-Psychological Issues of Safety in Emergency Situations, 2020, , 36-46.	0.2	1
184	Serological Biomarker Panel in Diagnosis of Atrophic Gastritis and <i>Helicobacter pylori</i> Infection in Gastroscopy Referral Patients: Clinical Validation of the New-Generation GastroPanel® Test. Anticancer Research, 2021, 41, 5527-5537.	0.5	11
185	Proteases in Helicobacter pylori-Mediated Diseases. , 2006, , 61-87.		1
186	A non-invasive method for the diagnosis of upper GI diseases. Acta Biomedica, 2018, 89, 40-43.	0.2	0

#	ARTICLE	IF	CITATIONS
187	Functional Dyspesia. Acta Biomedica, 2020, 91, e2020069.	0.2	2
188	Gastrin-17 Combined with CEA, CA12-5 and CA19-9 Improves the Sensitivity for the Diagnosis of Gastric Cancer. International Journal of General Medicine, 2021, Volume 14, 8087-8095.	0.8	8
189	Chronic Gastritis: Infectious, Non-infectious (Autoimmune, Chemical, Granulomatous), Chronic Superficial and Diffuse Antral Gastritis. , 2022, , 77-90.		0
191	The Association of Trefoil Factors with Gastric Cancer and Premalignant Lesions: A Cross-Sectional Population-Based Cohort Study. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 625-632.	1.1	2
192	Serum Gastrin and Pepsinogen Levels after Administration of Acid Secretion Inhibitors for Ulcers due to Endoscopic Submucosal Dissection in Patients with Early Gastric Cancer. Gastroenterology Research and Practice, 2022, 2022, 1-8.	0.7	1
193	Frequency of Helicobacter pylori Infection in Patients with Peptic Ulcer Referred to the Endoscopy Departments of Khorramabad City Hospitals, Iran, During 2013-2016. Infectious Disorders - Drug Targets, 2022, 22, .	0.4	1
194	Nanozyme enhanced magnetic immunoassay for dual-mode detection of gastrin-17. Analyst, The, 2022, 147, 1678-1687.	1.7	10
195	Accuracy of Serum Biomarker Panel (GastroPanel [®]) in the Diagnosis of Atrophic Gastritis of the Corpus. Systematic Review and Meta-analysis. Anticancer Research, 2022, 42, 1679-1696.	0.5	6
196	Serum Pepsinogens Combined with New Biomarkers Testing Using Chemiluminescent Enzyme Immunoassay for Non-Invasive Diagnosis of Atrophic Gastritis: A Prospective, Multicenter Study. Diagnostics, 2022, 12, 695.	1.3	3
200	Mechanisms for the Sex-Specific Effect of <i>H. Pylori</i> on Risk of Gastroesophageal Reflux Disease and Barrett's Esophagus. Cancer Epidemiology Biomarkers and Prevention, 2022, 31, 1630-1637.	1.1	2
201	A double helix-shaped optical fiber sensor for non-endoscopic diagnosis of gastrin-17. Analyst, The, 0, , .	1.7	1
202	Analysis of the relation between elevated neutrophil lymphocyte ratio, and erythrocyte sedimentation rate in Helicobacter pylori positive chronic gastritis patients. International Journal of Advances in Medicine, 2022, 9, 1023.	0.0	0
203	Panel of serum biomarkers (GastroPanel) in diagnosis of atrophic gastritis and <i>Helicobacter pylori</i> infection: a protocol of systematic review and meta-analysis. BMJ Open, 2022, 12, e062849.	0.8	0
204	Development of amplified luminescent proximity homogeneous assay for quantitation of gastrin-17. Analytical Biochemistry, 2023, 662, 115016.	1.1	0
205	Improvement of Symptoms in Patients Affected by Chronic Atrophic Gastritis Using L-Cysteine (Acetium [®]). Digestive Diseases, 2023, 41, 198-205.	0.8	3
206	Appropriateness of Proton Pump Inhibitor Prescription Evaluated by Using Serological Markers. International Journal of Molecular Sciences, 2023, 24, 2378.	1.8	1
208	Circulating Proteins and Metabolite Biomarkers in Gastric Cancer: A Systematic Review and Meta-analysis. Archives of Medical Research, 2023, 54, 124-134.	1.5	1